---
id: 232
title: Pulmonary Tuberculosis (TB)
category: clinical_syndromes
subcategory: mycobacterial
tags: [tuberculosis, TB, RIPE, DOT, latent-TB, acid-fast-bacilli]
difficulty: high
---

## Question

How is pulmonary TB managed? Use **"RIPE × 2 Months → RI × 4 Months, DOT Preferred, Airborne Isolation"** framework.

## Answer

### **Clinical Presentation:**

**Primary TB (Initial Infection):**
- **Often asymptomatic** (90-95% develop latent TB)
- **Ghon complex** (parenchymal focus + lymph node)

**Reactivation TB (Secondary TB):**
- **Chronic cough** (>3 weeks, often productive)
- **Hemoptysis** (20-30%)
- **Fever, night sweats, weight loss** ("consumptive" symptoms)
- **Fatigue, anorexia**

**Physical Exam:**
- **Often unremarkable** (crackles, dullness if cavitary)

### **Diagnosis:**

**Imaging:**

**Chest X-Ray:**
- **Reactivation:** Upper lobe infiltrates, cavitation (apical/posterior segments)
- **Primary:** Lower/middle lobe infiltrates, lymphadenopathy
- **Miliary TB:** Diffuse micronodular pattern ("millet seeds")

**CT Chest:**
- **Tree-in-bud** opacities (endobronchial spread)
- **Cavitation, consolidation**

**Microbiologic:**

**Sputum AFB Smear:**
- **3 sputum samples** (early morning, induced if non-productive)
- **Sensitivity 50-80%** (requires 10,000 organisms/mL)
- **Positive smear = infectious** (airborne precautions)

**Sputum Culture (Gold Standard):**
- **Mycobacterial culture** (liquid media, MGIT)
- **Takes 2-6 weeks** (slow-growing)
- **Drug susceptibility testing** (essential)

**Nucleic Acid Amplification Test (NAAT):**
- **Xpert MTB/RIF** (PCR, detects *M. tuberculosis* + rifampin resistance)
- **Result in 2 hours**
- **Sensitivity 85-90%** (lower if smear-negative)

**Tuberculin Skin Test (TST) / Interferon-Gamma Release Assay (IGRA):**
- **Detects latent TB infection** (NOT active disease)
- **See latent TB card**

### **Treatment:**

**Active Pulmonary TB (Drug-Susceptible):**

**Intensive Phase (2 Months):**
- **RIPE:**
  - **R**ifampin 600mg PO daily (or 10 mg/kg)
  - **I**soniazid 300mg PO daily (or 5 mg/kg) + **pyridoxine 25-50mg daily** (prevent neuropathy)
  - **P**yrazinamide 1500-2000mg PO daily (or 25 mg/kg, max 2g)
  - **E**thambutol 1200-1600mg PO daily (or 15-20 mg/kg)

**Continuation Phase (4 Months):**
- **RI:**
  - **R**ifampin 600mg PO daily
  - **I**soniazid 300mg PO daily + **pyridoxine 25-50mg daily**

**Total Duration:** **6 months** (2 months RIPE + 4 months RI)

**Extend to 9 Months if:**
- **Cavitary disease + positive culture at 2 months**
- **HIV-positive with low CD4 (<100)**
- **Slow clinical/microbiologic response**

**Directly Observed Therapy (DOT):**
- **Preferred** (ensures adherence, prevents resistance)
- **In-person observation** of medication ingestion

**Alternative Dosing:**
- **Intermittent (3×/week):** After initial 2 weeks daily (DOT required)

### **Drug-Resistant TB:**

**Rifampin-Resistant (RR-TB):**
- **Detected by Xpert MTB/RIF**
- **Treat as MDR-TB**

**Multidrug-Resistant TB (MDR-TB):**
- **Resistant to rifampin + isoniazid**
- **Regimen:** Fluoroquinolone + bedaquiline + linezolid + others × 18-20 months
- **Consult TB expert**

**Extensively Drug-Resistant TB (XDR-TB):**
- **MDR-TB + resistance to fluoroquinolone + ≥1 second-line injectable**
- **High mortality** (40-60%)

### **Monitoring:**

**Clinical:**
- **Weekly initially** (assess adherence, side effects)
- **Monthly weight** (adjust doses)

**Sputum:**
- **Monthly smear + culture** until 2 consecutive negative cultures
- **Most convert by 2 months** (if not, consider resistance, non-adherence)

**Labs:**
- **Baseline:** LFTs, Cr, CBC, HIV, hepatitis B/C
- **Monthly LFTs** (if baseline abnormal or symptoms)
- **Visual acuity, color vision** (baseline + monthly if ethambutol, check for optic neuritis)

### **Infection Control:**

**Airborne Isolation:**
- **Negative pressure room**
- **N95 respirator** (healthcare workers)
- **Continue until:** 3 consecutive negative AFB smears (usually 2-4 weeks of treatment)

**Discharge Criteria:**
- **Clinical improvement**
- **3 consecutive negative AFB smears** (on separate days)
- **Adherence to therapy ensured** (DOT arranged)

### **Special Situations:**

**HIV-Positive:**
- **Same regimen** (RIPE × 6 months, extend to 9 months if cavitary + culture+ at 2 months)
- **Start ART within 2-8 weeks** of TB treatment (reduces mortality)
  - **Exception:** TB meningitis (delay ART 8 weeks, ↓IRIS risk)
- **Avoid efavirenz** (with rifampin if possible, drug interactions)

**Pregnancy:**
- **RIPE safe** (avoid streptomycin, fluoroquinolones)
- **Pyridoxine 25-50mg daily** (prevent neuropathy)

**Renal Insufficiency:**
- **Adjust doses** (ethambutol, pyrazinamide, isoniazid)

**Hepatic Disease:**
- **Avoid pyrazinamide** if severe liver disease
- **Monitor LFTs closely**

### **Side Effects:**

**Rifampin:**
- **Orange discoloration** (urine, tears, sweat)
- **Drug interactions** (induces CYP450)
- **Hepatotoxicity**

**Isoniazid:**
- **Peripheral neuropathy** (prevent with pyridoxine)
- **Hepatotoxicity** (monitor LFTs)

**Pyrazinamide:**
- **Hepatotoxicity, hyperuricemia**

**Ethambutol:**
- **Optic neuritis** (dose-related, reversible if caught early)
- **Monitor visual acuity, color vision monthly**

### **Latent TB Infection (LTBI):**
- **See separate card** (screening, treatment)

## Key Points

### **RIPE × 2 Months → RI × 4 Months:**
- **Total 6 months** (drug-susceptible pulmonary TB)
- **Extend to 9 months** if cavitary + culture+ at 2 months

### **Pyridoxine with Isoniazid:**
- **25-50mg daily** (prevent peripheral neuropathy)

### **DOT Preferred:**
- **Ensures adherence, prevents resistance**

### **Airborne Isolation Until 3 Negative Smears:**
- **N95 respirator, negative pressure room**

### **Xpert MTB/RIF:**
- **Rapid diagnosis** (2 hours)
- **Detects rifampin resistance** (indicator of MDR-TB)

### **Clinical Pearls:**
- **RIPE × 2 months** → **RI × 4 months** (total 6 months)
- **Pyridoxine 25-50mg daily** (with isoniazid, prevent neuropathy)
- **DOT preferred** (ensures adherence)
- **Airborne isolation** until 3 negative smears
- **Xpert MTB/RIF:** Rapid diagnosis + rifampin resistance detection
- **Extend to 9 months:** Cavitary + culture+ at 2 months
- **HIV:** Start ART within 2-8 weeks (except TB meningitis, delay 8 weeks)

## Sources

- [CDC: Treatment of Tuberculosis 2024]
- [ATS/CDC/IDSA: TB Guidelines 2024]

## Media

N/A
